Lot-to-lot variation of unfractionated heparin using the anti-factor Xa assay.

被引：0
|
作者：
Pullen, GE
Siegel, JE
Goodell, LA
机构：
[1] Robert Wood Johnson Univ Hosp, New Brunswick, NJ USA
[2] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[3] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Newark, NJ 07103 USA
来源：
AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2002年 / 118卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
95
引用
收藏
页码：648 / 649
页数：2
相关论文
共 50 条
  • [21] Lot-to-lot variability in HLA antibody screening using a multiplexed bead-based assay
    Gandhi, Manish J.
    Carrick, Danielle M.
    Jenkins, Sarah
    De Goey, Steven
    Ploeger, Nancy A.
    Wilson, Gregory A.
    Lee, Jar How
    Winters, Jeffrey L.
    Stubbs, James R.
    Toy, Pearl
    Norris, Philip J.
    TRANSFUSION, 2013, 53 (09) : 1940 - 1947
  • [22] CLINICAL SIGNIFICANCE OF ANTI-FACTOR XA ASSAY
    ODEGARD, OR
    ABILDGAARD, U
    ACTA MEDICA SCANDINAVICA, 1978, : 19 - 19
  • [23] Interlaboratory Precision in the Monitoring of Unfractionated Heparin Using the Anti-Factor Xa-Correlated Activated Partial Thromboplastin Time
    Cuker, Adam
    Ptashkin, Beverly
    Konkle, Barbara A.
    Pipe, Steven W.
    Whinna, Herbert C.
    Zheng, X. Long
    Cines, Douglas B.
    Pollak, Eleanor
    BLOOD, 2008, 112 (11) : 166 - 166
  • [24] Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time
    Cuker, A.
    Ptashkin, B.
    Konkle, B. A.
    Pipe, S. W.
    Whinna, H. C.
    Zheng, X. L.
    Cines, D. B.
    Pollak, E. S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (01) : 80 - 86
  • [25] The contribution of lot-to-lot variation to the measurement uncertainty of an LC-MS-based multi-mycotoxin assay
    Stadler, David
    Sulyok, Michael
    Schuhmacher, Rainer
    Berthiller, Franz
    Krska, Rudolf
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2018, 410 (18) : 4409 - 4418
  • [26] Monitoring unfractionated heparin (UFH) therapy: Which anti factor Xa assay is appropriate?
    Ignjatovic, Vera
    Summerhayes, Robyn
    Gan, Andrew
    Than, Jenny
    Chan, Anthony
    Cochrane, Andrew
    Bennett, Martin
    Horton, Stephen
    Shann, Frank
    Lane, Geoff
    Ross-Smith, Maree
    Monagle, Paul
    THROMBOSIS RESEARCH, 2007, 120 (03) : 347 - 351
  • [27] Unfractionated Heparin Use in Children: Clinical Outcomes in a Pediatric Cohort Managed Using an Anti-Factor Xa Based Nomogram
    Saini, Surbhi
    Harsh, Katherine L.
    Stanek, Joseph R.
    O'Brien, Sarah
    Dunn, Amy L.
    Kumar, Riten
    BLOOD, 2017, 130
  • [28] The contribution of lot-to-lot variation to the measurement uncertainty of an LC-MS-based multi-mycotoxin assay
    David Stadler
    Michael Sulyok
    Rainer Schuhmacher
    Franz Berthiller
    Rudolf Krska
    Analytical and Bioanalytical Chemistry, 2018, 410 : 4409 - 4418
  • [29] LACK OF STANDARDIZATION OF THE ANTI-FACTOR (F)XA ACTIVITY REAGENTS USED IN MONITORING TREATMENTS WITH UNFRACTIONATED HEPARIN
    Toulon, Pierre
    Smahi, Motalib
    van Essen-Hollestelle, Martine
    De Pooter, Neila
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2019, 41 : 175 - 175
  • [30] Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels
    Schechter, T.
    Finkelstein, Y.
    Ali, M.
    Kahr, W. H.
    Williams, S.
    Chan, A. K.
    Deveber, G.
    Brandao, L. R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (03) : 368 - 374
12345